Plus Therapeutics announces publication of results on 186Re Obisbemeda

Plus Therapeutics (PSTV) announces the publication of results in a peer-reviewed manuscript titled, “Treatment of Recurrent Glioma by Rhenium Obisbemeda: a Phase 1 clinical trial” in the peer-reviewed medical journal Nature Communications. Key highlights from the publication: Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium, 186Re, Obisbemeda; No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment; Median overall survival was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months; Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated; Patients receiving greater than100 Gy had a median OS of 17 months, compared to 6 months for those receiving less than100 Gy; Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy